



UNIVERSITY OF LEEDS

This is a repository copy of *A trans-acting cyclase off-loading strategy for non-ribosomal peptide synthetases*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/144500/>

Version: Accepted Version

Article:

Thankachan, D, Fazal, A, Francis, D et al. (3 more authors) (2019) A trans-acting cyclase off-loading strategy for non-ribosomal peptide synthetases. *ACS Chemical Biology*, 14 (5). pp. 845-849. ISSN 1554-8929

<https://doi.org/10.1021/acscchembio.9b00095>

Copyright © 2019 American Chemical Society. This is an author produced version of a paper published in *ACS Chemical Biology*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 **A trans-acting cyclase off-loading strategy for non-ribosomal peptide synthetases**

2 Divya Thankachan^{1,3†}, Asif Fazal^{1,2,3†}, Daniel Francis^{1,2,3}, Lijiang Song⁴, Michael E. Webb^{2,3}, Ryan

3 F. Seipke^{1,3*}

4 ¹School of Molecular and Cellular Biology, ²School of Chemistry, ³Astbury Centre for Structural
5 Molecular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom

6 ⁴Department of Chemistry, University of Warwick, Coventry, CV4 7AL, United Kingdom

7 †Authors contributed equally to this work

8 *Corresponding author:

9 Ryan F. Seipke

10 E-mail: r.seipke@leeds.ac.uk

11

12 **Abstract**

13 The terminal step in the biosynthesis of non-ribosomal peptides is the hydrolytic release, and
14 frequently, macrocyclization of an aminoacyl-S-thioester by an embedded thioesterase. The
15 surugamide biosynthetic pathway is composed of two NRPS assembly lines where one produces
16 surugamide A, which is a cyclic octapeptide, and the other produces surugamide F, a linear
17 decapeptide. The terminal module of each system lacks an embedded thioesterase, which led us to
18 question how the peptides are released from the assembly line (and cyclized in the case of surugamide
19 A). We characterized a cyclase belonging to the β -lactamase superfamily (SurE) *in vivo* and
20 established that it is a trans-acting release factor for both compounds and verified this functionality
21 *in vitro* with a thioester mimic of linear surugamide A. Using bioinformatics, we estimate that ~11%
22 of filamentous Actinobacteria harbor an NRPS system lacking an embedded thioesterase and instead
23 employ a trans-acting cyclase. This study expands the paradigmatic understanding of how non-
24 ribosomal peptides are released from the terminal PCP and adds a new dimension to the synthetic
25 biology toolkit.

26 Non-ribosomal peptides (NRPs) are a large family of structurally complex and diverse natural
27 products, often with biologically and therapeutically relevant activities. They are synthesized by large
28 multifunctional enzymes called non-ribosomal peptide synthetases (NRPSs), which are organised
29 into relatively independently functioning modules that work in an assembly line-like manner until the
30 final polypeptide structure is generated.¹ During biosynthesis, the growing peptide chain remains
31 covalently linked to the 4'-phosphopantetheinyl cofactor of the peptidyl carrier protein (PCP)
32 domains. The terminal module usually possesses a C-terminal thioesterase (TE) domain, which off-
33 loads the polypeptide intermediate from the PCP on to a conserved serine residue whereby either a
34 hydrolytic or macrocyclization reaction occurs to produce the mature peptide.²


35 Surugamide A (**1**) and associated minor products B-E (**2-5**) are cyclic octapeptides initially
36 identified from *Streptomyces* sp. JAMM992 as inhibitors of cathepsin B, which also possess
37 antibacterial activity.^{3,4} Identification of the surugamide (sur) biosynthetic gene cluster (BGC) from
38 this organism revealed the presence of four NRPS genes (surABCD), which encoded 18 biosynthetic
39 modules (**Figure 1, Scheme 1**). The eight modules encoded by SurAD were consistent with the
40 biosynthesis of **1-5**, whereas the remaining 10 modules encoded by SurBC were shown to direct the
41 biosynthesis of an unrelated linear decapeptide named, surugamide F (**7**), which is structurally similar
42 to gramicidin A.⁵ *S. albus* J1074 was recently shown to produce surugamides, including an unusual
43 derivative named acyl-surugamide A (**6**), which has antifungal bioactivity.^{6,7} We identified the same
44 BGC in a related strain, *S. albus* S4⁸ and verified that it produced the major products **1** and **7** using
45 LC-HRMS (**Figures S1-S5**). An intriguing feature of the sur BGC harbored by these organisms is
46 that the terminal biosynthetic modules of SurC and SurD lack an integrated thioesterase domain and
47 alternative off-loading mechanisms such as hydrolytic condensation or reductase domains.

48

49

50

51




52

53 **Figure 1. The surugamide (sur) biosynthetic gene cluster (BGC).** Schematic representation of the
 54 sur BGC and domain organization of SurAD, which make cyclic surugamides (1-6) and SurBC,
 55 which makes surugamide F (7). A, adenylation domain; C, condensation domain; E, epimerase
 56 domain; AMPA, 3-amino-2-methylpropionic acid. Grey ovals indicate peptidylcarrier proteins.

57

58



59

60

61

Scheme 1. Structures of surugamides.

62

63

64

65

66

67


The absence of an obvious cis-acting mechanism for off-loading the final peptide from the terminal PCP domains of SurC and SurD led us to hypothesize that one or more trans-acting release factors may be encoded by genes within the sur BGC. Inspection of other genes within the BGC revealed two candidates, which we named surF and surE, that may perform this role. The surF gene product belongs to InterPro Family IPR029058, which includes enzymes with the characteristic alpha/beta hydrolase fold harbored by thioesterases.⁹ Standalone proofreading thioesterases (so-

68 called type II thioesterases) are relatively common within NRPS biosynthetic systems, where they
69 remove aberrant thioester intermediates from the assembly line.¹⁰ However, SurF is bioinformatically
70 inconsistent with this functionality. For instance, SurF belongs to IPR029058, while type II
71 thioesterases belong to IPR1223; it also possesses a hydrolase signature motif (GxSxG) of GTSLG,
72 which differs to that of GHSMG for established type II thioesterases.¹¹ Therefore, we investigated
73 the possibility that surF encoded a trans-acting release factor. If this were the case, then its deletion
74 would preclude detection of mature surugamides. To test this hypothesis, we deleted surF in *S. albus*
75 S4 and assessed the resulting mutant strain (Δ surF) for its ability to produce **1** and **7**. LC-HRMS
76 analysis of chemical extracts prepared from the Δ surF strain revealed that surF is not essential for
77 the production of **1** or **7** (**Figure S6**), indicating that SurF is unlikely to be a factor that off-loads the
78 terminal amino-acyl-S-thioester intermediates from the assembly line, but instead may be a type II
79 thioesterase with an unusual hydrolase signature motif.

80 The surE gene encodes a protein belonging to InterPro Family IPR012338, indicating it is a
81 member of the β -lactamase superfamily, which includes transpeptidases and esterases. Analysis of
82 SurE indicates that it possesses the Ser-Lys-Tyr-His tetrad active site motif the characteristic of Class
83 C β -lactamases (**Figure S7**) and that it is phylogenetically distinct from type I and type II thioesterases
84 (**Figure S8**). A recent genetic study of mannopeptimycin biosynthesis suggested that a member of
85 this protein family, MppK (39% shared amino acid identity with SurE) functioned as a
86 termination/cyclization protein.¹² Therefore, in order to test whether surE encodes a trans-acting off-
87 loading factor, we deleted surE in *S. albus* S4 and tested the resulting mutant strain for its ability to
88 produce **1** and **7** by LC-HRMS. This revealed that only trace amounts of **1** and **7** were detectable in
89 the extract prepared from the Δ surE strain (**Figure 2**). Complementation of the Δ surE mutant with
90 pDT2, which contained the surE gene under the control of the constitutive ermE* promoter, restored
91 production of both **1** and **7** to near wild-type levels and verified that loss of their production was not
92 due to other mutational events (**Figure 2**). Taking these findings together, we conclude that SurE is
93 required for the production of both **1** and **7**, presumably because it off-loads the linear aminoacyl-S-

94 thioester intermediate of surugamide A and performs a head-to-tail cyclisation reaction to result in **1**
95 and simply hydrolytically releases the linear aminoacyl-S-thioester intermediate of surugamide F to
96 result in **7**.

97




98

99 **Figure 2. *surE* is essential for the production of surugamide A and surugamide F.** LC-HRMS
100 analysis of chemical extracts prepared from the indicated strains. The m/z corresponding to the
101 $[M+H]^+$ ions derived from **1** (black, $C_{48}H_{81}N_9O_8$) and **7** (red, $C_{52}H_{85}N_{11}O_{12}$) are shown. The intensity
102 scale for EICs is 1×10^6 for **1** and is 1×10^5 for **7**.
103

104 We sought to reconstitute these reactions *in vitro* to corroborate our *in vivo* data and to
105 unambiguously determine the function of SurE. SurE was overproduced and purified from *E. coli* as
106 an N-terminal hexahistidine tagged variant ($(His)_6$ SurE, **Figure S9**). The cost of the AMPA residue
107 within **7** led us to first verify the functionality of SurE using a thioester mimic of linear **1** before
108 embarking on synthesis of the equivalent mimic for **7**. Thus, we synthesized an N-acetylcysteamine
109 (SNAC) thioester mimic of **1** (**Figures S10-S13**) and assessed the ability of SurE to utilise this
110 substrate. When SurE is incubated with SNAC-surugamide A (**8**) it catalyzes the formation of **1** as
111 judged by LC-HRMSMS (**Figure 3, Figure S14-S16**). These data were recently corroborated by a
112 report in which an ortholog of SurE from *S. albidoflavus* NBRC12854 catalyzed the same reaction *in*
113 *vitro* with the SNAC thioester mimic of **2**, a shunt product of the pathway.¹³ While our chemical
114 synthesis of a thioester mimic of **7** was in progress, its synthesis and utilization by SurE was reported
115 elsewhere.¹⁴ Surprisingly, surugamide F was not the major product *in vitro* and instead SurE produced

116 a head-to-tail cyclized variant named cyclosurugamide F, which was also retrospectively observed in
117 low abundance within a crude chemical extract generated from the producing organism.¹⁴ The
118 authors proposed an intriguing possibility that a cytosolic peptidase may hydrolyze the bond
119 generated by SurE to result in **7**.¹⁴ Taken together, our data and that of others unambiguously
120 demonstrate that SurE is a trans-acting cyclase that off-loads the terminal linear aminoacyl-S-
121 thioester intermediates of surugamides A and F and performs head-to-tail cyclisation reactions to
122 result in **1** and **7**.



123
124

125 **Figure 3. LC-HRMS analysis of in vitro SurE reaction with SNAC-surugamide A.** (The m/z
126 corresponding to the $[M+H]^{2+}$ ions derived from **1** (blue, $C_{48}H_{81}N_9O_8$) and **8** (red, $C_{52}H_{90}N_{10}O_9S$) are
127 shown. The intensity scale for all EICs is 1×10^6 .


128
129

130 Although the hypothesis was not rigorously evaluated, MppK was suggested to perform a
131 function analogous to SurE during the biosynthesis of mannopeptimycin¹² and putative orthologs
132 have been observed within the desotamide and ulleungmycin BGCs.^{15,16} This led us to evaluate how
133 widespread the SurE off-loading mechanism may be within NRPS biosynthetic systems. To do this,

134 we identified organisms harboring sententious orthologs of SurABCD and SurE using a
135 multigeneblast database that we previously built with 1,421 filamentous Actinobacterial
136 genomes.^{17,18} Next, the candidate genomes that arose from this analysis were subjected to analysis by
137 antiSMASH 4.1.0¹⁹ and the corresponding output was used to manually curate a list of NRPS
138 biosynthetic systems lacking an embedded TE domain, but harboring an adjacent SurE ortholog.
139 These criteria were satisfied by 174 NRPS systems harbored by 166 organisms in our dataset,
140 suggesting that overall, ~11% of filamentous Actinobacteria harbor an NRPS biosynthetic system
141 that utilizes a release strategy involving a trans-acting cyclase belonging to the β -lactamase
142 superfamily.

143 Anecdotal observations during the manual curation of antiSMASH analyses suggested that
144 several of the identified biosynthetic systems were related to one another. In order to explore this
145 possibility, we used BiG-SCAPE²⁰ to generate a BGC similarity network of the NRPS systems
146 identified above (**Figure 4, Table S1**). The final network was grouped into 15 subnetworks and 12
147 singletons. In addition to 174 nodes for the BGCs identified here, three additional nodes were
148 generated from entries within the MIBiG database of experimentally characterized BGCs²¹; these
149 three nodes correspond to BGCs that direct the biosynthesis of surugamides⁵, ulleungmycin¹⁶ and
150 dechlorocuracomycin²². Surprisingly, the BGCs for desotamide¹⁵ and mannopeptimycin¹², which are
151 also present within the MIBiG database, were not resolved within the network, implying that they are
152 distantly related systems. The number of modules encoded within a biosynthetic system, which
153 ranged from 4-10 modules and is color-coded within Figure 4, was a major factor that influenced
154 subnetwork formation (**Figure 4, Table S1**). SurE itself is capable of accepting amino-S-acyl
155 thioester substrates 8 and 10 amino acid residues in length, however our bioinformatics analyses
156 suggests that SurE and/or its orthologs may be able to utilise substrates composed of just four amino
157 acid residues. Future studies will interrogate the molecular rules underpinning substrate recognition
158 by SurE.

159



160

161

162 **Figure 4. Gene cluster similarity network for NRPS BGCs without an embedded thioesterase**
 163 **but encoding a SurE ortholog.** Each node represents a BGC and is color-coded based on the number
 164 of its putative biosynthetic modules. The node table is shown in **Table S1**.
 165

166 In summary, we have identified and characterized in vivo and in vitro a trans-acting release
 167 factor, SurE, that off-loads surugamides via macrolactamization from their respective assembly lines.
 168 Based on our bioinformatic analyses, we propose that this release mechanism is relatively widespread
 169 among Actinobacteria. This work expands the paradigmatic understanding of how non-ribosomal
 170 peptides are off-loaded from terminal PCP domains in NRPS assembly lines and in the process has
 171 identified a standalone (thereby more amenable to augmentation) release factor that could aid
 172 reengineering of non-ribosomal peptide biosynthesis. As access to genomic data increases and
 173 bioinformatics approaches become more robust and sophisticated, we should expect and indeed look
 174 forward to discovering the myriad of ways nature has evolved biosynthetic processes.

175 **Associated content**

176 **Supporting information**

177 The supporting information is available free of charge via the internet at <http://pubs.ac.org>.

178 Experimental details, LC-MS and NMR spectra and supporting figures and tables (PDF)

179 **Acknowledgements**

180 This work was supported by Biotechnology and Biological Sciences Research Council
181 Natural Products Discovery and Bioengineering Network grant POC038 awarded to RFS. DT and
182 AF were supported by PhD studentships funded by the University of Leeds.

183 **References**

- 184 (1) Süßmuth, R. D., and Mainz, A. (2017) Nonribosomal peptide synthesis-principles and
185 prospects. *Angew. Chem. Int. Ed.* 129, 3824–3878.
- 186 (2) Du, L., and Lou, L. (2010) PKS and NRPS release mechanisms. *Nat. Prod. Rep.* 27, 255–278.
- 187 (3) Takada, K., Ninomiya, A., Naruse, M., Sun, Y., Miyazaki, M., Nogi, Y., Okada, S., and
188 Matsunaga, S. (2013) Surugamides A–E, cyclic octapeptides with four D-Amino acid residues,
189 from a marine *Streptomyces* sp.: LC–MS-aided inspection of partial hydrolysates for the distinction
190 of D- and L-amino acid residues in the sequence. *J. Org. Chem.* 78, 6746–6750.
- 191 (4) Wang, X., Shaaban, K. A., Elshahawi, S. I., Ponomareva, L. V., Sunkara, M., Copley, G. C.,
192 Hower, J. C., Morris, A. J., Kharel, M. K., and Thorson, J. S. (2014) Mullinamides A and B, new
193 cyclopeptides produced by the ruth mullins coal mine fire isolate *Streptomyces* sp. RM-27-46. *J*
194 *Antibiot* 67, 571–575.
- 195 (5) Ninomiya, A., Katsuyama, Y., Kuranaga, T., Miyazaki, M., Nogi, Y., Okada, S., Wakimoto, T.,
196 Ohnishi, Y., Matsunaga, S., and Takada, K. (2016) Biosynthetic gene cluster for surugamide A
197 encompasses an unrelated decapeptide, surugamide F. *ChemBioChem* 17, 1709–1712.
- 198 (6) Mohimani, H., Gurevich, A., Mikheenko, A., Garg, N., Nothias, L.-F., Ninomiya, A., Takada,
199 K., Dorrestein, P. C., and Pevzner, P. A. (2016) Dereplication of peptidic natural products through
200 database search of mass spectra. *Nat. Chem. Biol.* 13, 30–37.
- 201 (7) Xu, F., Nazari, B., Moon, K., Bushin, L. B., and Seyedsayamdost, M. R. (2017) Discovery of a
202 cryptic antifungal compound from *Streptomyces albus* J1074 using high-throughput elicitor screens.
203 *J. Am. Chem. Soc.* 139, 9203–9212.
- 204 (8) Seipke, R. F. (2015) Strain-level diversity of secondary metabolism in *Streptomyces albus*.
205 *PLoS ONE* 10, e0116457–14.
- 206 (9) Cantu, D. C., Chen, Y., and Reilly, P. J. (2010) Thioesterases: a new perspective based on their
207 primary and tertiary structures. *Protein Sci.* 19, 1281–1295.

208 (10) Heathcote, M. L., Staunton, J., and Leadlay, P. F. (2001) Role of type II thioesterases:
209 evidence for removal of short acyl chains produced by aberrant decarboxylation of chain extender
210 units. *Chem. Biol.* 8, 207–220.

211 (11) Nakamura, H., Wang, J. X., and Balskus, E. P. (2015) Assembly line termination in
212 cylindrocyclophane biosynthesis: discovery of an editing type II thioesterase domain in a type I
213 polyketide synthase. *Chem. Sci.* 6, 3816–3822.

214 (12) Magarvey, N. A., Haltli, B., He, M., Greenstein, M., and Hucul, J. A. (2006) Biosynthetic
215 pathway for mannopeptimycins, lipoglycopeptide antibiotics active against drug-resistant Gram-
216 positive pathogens. *Antimicrob. Agents Chemother.* 50, 2167–2177.

217 (13) Kuranaga, T., Matsuda, K., Sano, A., Kobayashi, M., Ninomiya, A., Takada, K., Matsunaga,
218 S., and Wakimoto, T. (2018) Total synthesis of a non-ribosomal peptide surugamide B identifies a
219 new offloading cyclase family. *Angew. Chem. Int. Ed.* 57, 9447–9451.

220 (14) Matsuda, K., Kobayashi, M., Kuranaga, T., Takada, K., Ikeda, H., Matsunaga, S., and
221 Wakimoto, T. (2019) SurE is a trans-acting thioesterase cyclizing two distinct non-ribosomal
222 peptides. *Org. Biomol. Chem.* 17, 1058–1061.

223 (15) Li, Q., Song, Y., Qin, X., Zhang, X., Sun, A., and Ju, J. (2015) Identification of the
224 biosynthetic gene cluster for the anti-infective desotamides and production of a new analogue in a
225 heterologous host. *J. Nat. Prod.* 78, 944–948.

226 (16) Son, S., Hong, Y.-S., Jang, M., Heo, K. T., Lee, B., Jang, J.-P., Kim, J.-W., Ryoo, I.-J., Kim,
227 W.-G., Ko, S.-K., Kim, B. Y., Jang, J.-H., and Ahn, J. S. (2017) Genomics-driven discovery of
228 chlorinated cyclic hexapeptides ulleungmycins A and B from a *Streptomyces* species. *J. Nat. Prod.*
229 80, 3025–3031.

230 (17) Medema, M. H., Medema, M. H., Takano, E., Takano, E., Breitling, R., and Breitling, R.
231 (2013) Detecting sequence homology at the gene cluster level with MultiGeneBlast. *Mol. Biol.*
232 *Evol.* 30, 1218–1223.

233 (18) Joynt, R., and Seipke, R. F. (2018) A phylogenetic and evolutionary analysis of antimycin
234 biosynthesis. *Microbiology* 164, 28–39.

235 (19) Blin, K., Wolf, T., Chevrette, M. G., Lu, X., Schwalen, C. J., Kautsar, S. A., Suarez Duran, H.
236 G., de los Santos, E. L. C., Kim, H. U., Nave, M., Dickschat, J. S., Mitchell, D. A., Shelest, E.,
237 Breitling, R., Takano, E., Lee, S. Y., Weber, T., and Medema, M. H. (2017) antiSMASH 4.0—
238 improvements in chemistry prediction and gene cluster boundary identification. *Nucleic Acids Res.*
239 45, W36–W41.

240 (20) Navarro-Muñoz, J., Selem Mojica, N., Mallowney, M., Kautsar, S., Tryon, J., Parkinson, E.,
241 De Los Santos, E., Yeong, M., Cruz-Morales, P., Abubucker, S., Roeters, A., Lokhorst, W.,
242 Fernandez-Guerra, A., Teresa Dias Cappelini, L., Thomson, R., Metcalf, W., Kelleher, N., Barona-
243 Gómez, F., and Medema, M. H. (2018) A computational framework for systematic exploration of
244 biosynthetic diversity from large-scale genomic data. *bioRxiv* 445270; doi:
245 <https://doi.org/10.1101/445270>.

246 (21) Medema, M. H., Kottmann, R., Yilmaz, P., Cummings, M., Biggins, J. B., Blin, K., de Bruijn,
247 I., Chooi, Y. H., Claesen, J., Coates, R. C., Cruz-Morales, P., Duddela, S., Düsterhus, S., Edwards,
248 D. J., Fewer, D. P., Garg, N., Geiger, C., Gomez-Escribano, J. P., Greule, A., Hadjithomas, M.,
249 Haines, A. S., Helfrich, E. J. N., Hillwig, M. L., Ishida, K., Jones, A. C., Jones, C. S., Jungmann,
250 K., Kegler, C., Kim, H. U., Kötter, P., Krug, D., Masschelein, J., Melnik, A. V., Mantovani, S. M.,
251 Monroe, E. A., Moore, M., Moss, N., Nützmann, H.-W., Pan, G., Pati, A., Petras, D., Reen, F. J.,
252 Rosconi, F., Rui, Z., Tian, Z., Tobias, N. J., Tsunematsu, Y., Wiemann, P., Wyckoff, E., Yan, X.,
253 Yim, G., Yu, F., Xie, Y., Aigle, B., Apel, A. K., Balibar, C. J., Balskus, E. P., Barona-Gómez, F.,
254 Bechthold, A., Bode, H. B., Borriss, R., Brady, S. F., Brakhage, A. A., Caffrey, P., Cheng, Y.-Q.,
255 Clardy, J., Cox, R. J., De Mot, R., Donadio, S., Donia, M. S., van der Donk, W. A., Dorrestein, P.
256 C., Doyle, S., Driessen, A. J. M., Ehling-Schulz, M., Entian, K.-D., Fischbach, M. A., Gerwick, L.,
257 Gerwick, W. H., Gross, H., Gust, B., Hertweck, C., Höfte, M., Jensen, S. E., Ju, J., Katz, L.,
258 Kaysser, L., Klassen, J. L., Keller, N. P., Kormanec, J., Kuipers, O. P., Kuzuyama, T., Kyrpides, N.

259 C., Kwon, H.-J., Lautru, S., Lavigne, R., Lee, C. Y., Linquan, B., Liu, X., Liu, W., Luzhetskyy, A.,
260 Mahmud, T., Mast, Y., Mendez, C., Metsä-Ketelä, M., Micklefield, J., Mitchell, D. A., Moore, B.
261 S., Moreira, L. M., Müller, R., Neilan, B. A., Nett, M., Nielsen, J., O'Gara, F., Oikawa, H.,
262 Osbourn, A., Osburne, M. S., Ostash, B., Payne, S. M., Pernodet, J.-L., Petricek, M., Piel, J., Ploux,
263 O., Raaijmakers, J. M., Salas, J. A., Schmitt, E. K., Scott, B., Seipke, R. F., Ben Shen, Sherman, D.
264 H., Sivonen, K., Smanski, M. J., Sosio, M., Stegmann, E., Süßmuth, R. D., Tahlan, K., Thomas, C.
265 M., Tang, Y., Truman, A. W., Viaud, M., Walton, J. D., Walsh, C. T., Weber, T., van Wezel, G. P.,
266 Wilkinson, B., Willey, J. M., Wohlleben, W., Wright, G. D., Ziemert, N., Zhang, C., Zotchev, S. B.,
267 Breitling, R., Takano, E., and Glöckner, F. O. (2015) Minimum Information about a Biosynthetic
268 Gene cluster. *Nat. Chem. Biol.* 11, 625–631.

269 (22) Kaweewan, I., Komaki, H., Hemmi, H., and Kodani, S. (2017) Isolation and Structure
270 Determination of New Antibacterial Peptide Curacomycin Based on Genome Mining. *Asian J. Org.*
271 *Chem.* 6, 1838–1844.

Supporting Information

A trans-acting cyclase off-loading strategy for non-ribosomal peptide synthetase

Divya Thankachan^{1,3†}, Asif Fazal^{1,2,3†}, Daniel Francis^{1,2,3}, Lijiang Song⁴, Michael E. Webb^{2,3}, Ryan F. Seipke^{1,3*}

¹School of Molecular and Cellular Biology, ²School of Chemistry, ³Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom

⁴Department of Chemistry, University of Warwick, Coventry, CV4 7AL, United Kingdom

***Corresponding author:**

Ryan F. Seipke

E-mail: r.seipke@leeds.ac.uk

Table of Contents

Supporting figures and tables

Experimental procedures

Figure S1. Streptomyces albus S4 produces surugamide A (**1**) and surugamide F (**7**).

Figure S2. The measured and simulated mass spectra for **1**.

Figure S3. The measured and simulated mass spectra for **7**.

Figure S4. MS2 fragmentation of **1**.

Figure S5. MS2 fragmentation of **7**.

Figure S6. SurF is not essential for the production of **1** or **7**.

Figure S7. MUSCLE alignment of SurE with closely related proteins.

Figure S8. Maximum likelihood phylogeny of SurE and related proteins.

Figure S9. SDS-PAGE analysis of purified (His)₆SurE.

Figure S10. LC-HRMS analysis of **8**.

Figure S11. The measured and simulated mass spectra for **8**.

Figure S12. MS2 fragmentation of **8**.

Figure S13. H¹ NMR of **8**.

Figure S14. The measured and simulated mass spectra for **1** produced by SurE in vitro.

Figure S15. MS2 fragmentation of **1** produced by SurE in vitro.

Figure S16. LC-HRMS analysis of in vitro reactions with **8**.

Table S1. NRPS biosynthetic systems lacking an embedded thioesterase domain and with an adjacent SurE orthologue.

Table S2. Oligonucleotide primers used in this study.

Table S3. Bacterial strains, cosmids and plasmids

Growth media, strains, cosmids, plasmids and other reagents. *Escherichia coli* strains were cultivated using Lennox agar (LA) or broth (LB) and *Streptomyces* strains were propagated on mannitol-soya flour agar or ISP2 broth.¹ Culture media was supplemented with antibiotics as required at the following concentrations: apramycin (50 µg/ml), carbenicillin (100 µg/ml), hygromycin (75 µg/ml), kanamycin (50 µg/ml), nalidixic acid (25 µg/ml). Enzymes were purchased from New England Biolabs unless otherwise stated. Oligonucleotides were purchased from Integrated DNA Technologies and are described in **Table S2**. The DNA constructs and bacterial strains used in this study are listed in **Table S3**.

Construction and complementation of mutant strains. The *surE* and *surF* genes were deleted using the ReDirect PCR targeting system² with Cos994. Cos994 was identified by screening a previously constructed *S. albus* S4 cosmid library³ by PCR using primers DT159 and DT160, which targeted an internal fragment of *surF*. Cos994 was insert-end sequenced using primers RFS184 and RFS185 and the resulting reads were mapped to the *S. albus* S4 genome^{4,5} in order to establish the sequence of the cloned insert. Gene disruption cassettes consisting of an *oriT* and the apramycin resistance gene, *aac(3)IV* from pIJ773² were generated by PCR using primers DT161 and DT162 (*surE*), and DT167 and DT168 (*surF*) containing 40 nt of homology that included the start and stop codons of each gene and 37 nt upstream or downstream. The resulting gel purified PCR products were used to delete *surE* or *surF* from Cos994 by recombineering with *E. coli* GB05-red⁶. Mutagenised cosmids were electroporated into *E. coli* ET12567/pUZ8002 and subsequently mobilized to *S. albus* S4 by conjugation as described.¹ Transconjugants were selected for apramycin resistance and kanamycin sensitivity. The integrity of mutant strains was verified by PCR. The complemented Δ *surE* strain was generated as follows. The *surE* gene PCR amplified from *S. albus* S4 genomic and cloned into pIJ10257⁷ at the *NdeI* and *HindIII* sites. The resulting plasmid (pDT2) was sequenced using RFS582 and DT186 to verify the integrity of cloned insert and mobilised by conjugal transfer into the *S. albus* S4 Δ *surE*. The resulting strain was verified by PCR.

Generation of chemical extracts and LC-HRMS analysis. *S. albus* strains were first cultured in 10 ml of LB while shaking (220 rpm) at 30 °C for 3 days, at which point the entire culture was added to ISP2 broth (50 ml in a 250 ml flask) and incubated at 30 °C with shaking (180 rpm) for 4 days. Bacterial cells were removed by centrifugation, and metabolites were extracted from the supernatant twice with two volumes of ethyl acetate. Extracts were pooled and concentrated in vacuo. The remaining residue was resuspended in 0.7 ml of 100% MeOH. Two microliters of methanolic extract were injected into a Bruker MaXis Impact II mass spectrometer coupled with a Dionex 3000 RS UHPLC equipped with an Agilent C18 column (2.1 × 100 mm). The solvent system was as follows: solvent A, 0.1% formic acid in water; solvent B, 0.1% formic acid in acetonitrile. The following gradient was used: 0-5 min, 5% B; 5-20 min, 5-100% B; 20-25 min, 100% B; 25-27 min, 100-5% B. The flow rate was 0.2 ml/min. Calibration was achieved with 1 mM sodium formate at the beginning of each run.

Overproduction and Purification of Recombinant Protein. The *surE* PCR amplified from extracted *S. albus* S4 genomic DNA using primers DT206 and DT213 (**Table S2**). The resulting PCR product was gel purified and digested with *NdeI* and *XhoI* endonucleases, and ligated with T4 DNA ligase to pET28a cut with the same enzymes to result in pET28-*surE*. The integrity of the cloned insert was verified by DNA sequencing and subsequently used to transform *E. coli* BL21-Gold(DE3) (Agilent Technologies). For overproduction of the recombinant protein, a starter culture *E. coli* cells harboring pET28-*surE* were cultured overnight in 10 ml LB supplemented with kanamycin while shaking (180 rpm) at 37 °C. Five milliliters of the starter culture were used to inoculate 500 ml of Super Broth auto-induction media (Formedium) and cultured for 48 hours while shaking (180 rpm)

at 16°C. Bacterial cells were collected by centrifugation, resuspended in lysis buffer (50 mM HEPES, 500 mM NaCl, 10 mM imidazole, 1 mM EDTA, protease inhibitor, DNase I, pH 7.5) and lysed using an ultrasonic probe (40% power, 2 x 90 seconds, 1 pulse s⁻¹). Lysates were clarified by centrifugation and passed through a 20 ml BioRad Econo Pac column loaded with 3 ml Ni-NTA resin (Generon) by gravity flow. The resin was washed with two column volumes of wash buffer (50 mM HEPES, 200 mM NaCl, 50 mM imidazole, 1 mM EDTA, pH 7.5). Protein was eluted from the resin with elution buffer (50 mM HEPES, 200 mM NaCl, 300 mM imidazole, 1 mM EDTA, pH 7.5) and analysed by SDS-PAGE. Elution fractions containing the protein of interest were pooled and concentrated using an Amicon spin filter (Merck) and subjected to buffer exchange by dialysis into storage buffer (50 mM HEPES, 200 mM NaCl, pH 7.5).

Chemical Synthesis of SNAC-surugamide A. Linear surugamide A was synthesised as a protected peptide as follows. 2-Chlorotrityl resin (100 mg, 1.00-1.80 mmol g⁻¹) was swollen in DMF (10 ml) for 30 minutes. The resin was transferred to the peptide synthesiser and coupled twice with Fmoc D- Leu (1 mmol) using DIC (1 mmol) and Oxyma (1 mmol) for 30 minutes with microwave irradiation. The resin was washed with DMF (2 × 10ml) after the coupling step. Fmoc deprotection was conducted using 20% piperidine in DMF (2 × 10ml) and washed with DMF (2 × 10ml). The coupling and deprotection cycle was repeated using Fmoc D-Phe, Fmoc L-Ile, Fmoc L-Lys(Boc), Fmoc D-Ile, Fmoc L-Ile, Fmoc D-Ala and Boc L-Ile. The resin was filtered and washed successively with DMF (2 × 10ml) and DCM (2 × 10ml). The 2-chlorotrityl resin was deprotected using hexafluoroisopropanol in DCM (1:4, 3ml) for 2 hours after which time the resin was filtered and washed with DCM (3 × 10ml). The solvents were removed in vacuo resulting in an off-white solid which was used without further purification.

In vitro SNAC assay. The ability of (His)₆SurE to utilise SNAC-surugamide A was assessed in vitro using the following reaction conditions in a final volume of 100 µl: 50 mM HEPES (pH 7.5), 0.1 mM SNAC-surugamide A, 20 µg of (His)₆SurE. The enzymatic reaction or SNAC-surugamide A alone were incubated at 30 °C. After 5 hrs of incubation, samples were treated with 100 µL of 0.05% TFA and extracted with Phenomenex Strata-XL C18 (100 µm, 30 mg, 1 ml) solid-phase extraction column and a vacuum manifold. Metabolites were eluted from the column with 120 µl of 100 % methanol. The methanolic extract was either diluted 1:1 with 100% methanol or mixed 1:1 with crude natural product prior to centrifugation for 10 mins at 16,000g to remove any insoluble material before analysis by LC-HR-ESI MSMS on a Bruker MaXis Impact II TOF mass spectrometer equipped with a Dionex UltiMate 3000 high-performance liquid chromatography apparatus with conditions described previously⁸.

The crude protected peptide was dissolved in DCM (2 ml) to which was added DIC (63 mg, 0.5 mmol), HOBt (67 mg, 0.5 mmol) and N-acetylcysteamine (60 mg, 0.5 mmol). The solution was stirred at room temperature overnight followed by removal of solvent in vacuo. The crude thioester was globally deprotected by dissolving in 9:1 TFA:DCM and stirred at 0 °C to room temperature for 3 hours. The volatiles were removed in vacuo and the crude sample dissolved in cold water (10 ml). Ice cold diethyl ether was used to precipitate the peptide which was collected by centrifugation (4 °C). The crude SNAC peptide was purified by preparative HPLC using Agilent 1260 Mass Directed Preparative HPLC instrument equipped with a Phenomenex Kinetex EVO C18 column (5 µm, 100 × 21.2 mm). The solvent system was as follows: solvent A, 0.1% formic acid in water; solvent B, 0.1% formic acid in acetonitrile. The following gradient was used: 0-2 min, 5% B; 2-12 min, 5-95% B; 12-14 min, 95% B; 14-15 min, 100-5% B. The flow rate was 20 ml/min.) and solvent removed in vacuo resulting in the pure peptide as a white solid (8 mg). The final peptide was subjected to NMR spectroscopy on a JEOL ECA600 series II 600MHz NMR spectrometer ¹H NMR (600 MHz, D₂O)

7.29 – 7.26 (m, 2H), 7.23 – 7.19 (m, 3H), 4.68 (m, 1H), 4.41 (dd, J = 10.1, 3.9 Hz, 1H), 4.35 (q, J = 7.2 Hz, 1H), 4.25 (dd, J = 9.4, 5.3 Hz, 1H), 4.21 (d, J = 7.1 Hz, 1H), 4.02 (d, J = 8.0 Hz, 1H), 3.93 (d, J = 7.9 Hz, 1H), 3.70 (s, 1H), 3.24 (t, J = 6.3 Hz, 2H), 3.20 (dd, J = 14.1, 5.5 Hz, 1H), 2.96 – 2.82 (m, 6H), 1.86 (s, 3H), 1.80 (ddd, J = 9.9, 7.4, 4.5 Hz, 2H), 1.71 (tt, J = 11.4, 5.6 Hz, 1H), 1.67 – 1.52 (m, 8H), 1.45 – 1.32 (m, 4H), 1.31 (d, J = 7.2 Hz, 3H), 1.29 – 1.24 (m, 1H), 1.20 (ddd, J = 13.6, 7.5, 3.5 Hz, 1H), 1.17 – 1.02 (m, 4H), 0.94 (dt, J = 13.7, 7.8 Hz, 1H), 0.89 (d, J = 6.9 Hz, 3H), 0.85 – 0.80 (m, 14H), 0.77 (ddd, J = 7.8, 6.5, 1.3 Hz, 10H), 0.66 (t, J = 7.4 Hz, 3H), 0.49 (d, J = 6.9 Hz, 3H). 0.5 (d, J = 6.9 Hz, 3H); HMRSC₅₂H₉₁N₁₀O₉S⁺ [M+H]⁺ requires 1031.6686; found 1031.6712 (Δ 2.5ppm).

Bioinformatics analysis. A bespoke multigeneblast⁹ database of 1,421 Prokka-annotated¹⁰ Actinobacterial genomes (Genera: Actinobacteria, Actinomadura, Actinospica, Amycolatopsis, Kitasatospora, Micromonospora, Nocardia, Saccharopolyspora, Planomonospora, Pseudonocardia, Salinispora, Streptacidiphilus and Streptomyces) was previously constructed¹¹. SurABCDE were used as a multigeneblast query with the default settings. The resulting output was inspected manually to identify genomes harboring putative NRPS systems with an adjacent SurE ortholog. The resulting complete genomes and draft genome contigs harboring such systems were subjected to antiSMASH analysis (webserver version 4.1.0).¹² The resulting output was manually inspected to determine if the putative terminal biosynthetic module harbored an embedded TE domain. Systems harbored near the end of a contig were discarded in order to remove truncated genes from future analyses. In total, 174 NRPS BGCs were identified that appeared to lack an embedded thioesterase domain and harbor an adjacent SurE ortholog. The corresponding antiSMASH-generated GenBank files for these systems were redacted to remove all genes except those encoding the putative chemical scaffold and off-loading factor (i.e. putative NRPS genes and the SurE ortholog) in order to make generation the BGC similarity network more coherent. BiG-SCAPE¹³ was used with the redacted GenBank files to generate a BGC similarity network. The graphic displayed in Figure 4 was generated using Cytoscape 3.7.1¹⁴ and the raw BiG-SCAPE is available from via Figshare (<https://doi.org/10.6084/m9.figshare.7665494.v1>). The multi-sequence alignment depicted in Figure S7 was generated using the Geneious R8.1.7 implementation of MUSCLE.¹⁵ The phylogeny of SurE, β -lactamses and thioesterases was constructed from a MUSCLE multi-sequence alignment using the Geneious R8.1.7 implementation of PhyML 3.2.2.¹⁶ The thioesterase sequences used to construct the phylogeny were obtained from accession provided by.¹⁷




Figure S1. *Streptomyces albus* S4 produces surugamide A (**1**) and surugamide F (**7**). (A) LC-HRMS analysis of chemical extracts prepared from *S. albus* S4. The base peak chromatogram (BPC) and the m/z corresponding to the $[M+H]^+$ ions derived from surugamide A (red, $C_{48}H_{81}N_9O_8$) and surugamide F (green, $C_{52}H_{85}N_{11}O_{12}$) are shown.




Figure S2. The measured (red) and simulated (orange) $[M+H]^+$ mass spectra for surugamide A.




Figure S3. The measured (green) and simulated (orange) $[M+H]^+$ mass spectra for surugamide F.




Figure S4. MS2 fragmentation of surugamide A. Mapped fragments are color-coded. Green text indicates an unobserved ion.




Figure S5. MS2 fragmentation of surugamide F. Mapped fragments are color-coded.




Figure S6. SurF is not essential for the production of **1** or **7**. LC-HRMS analysis of chemical extracts prepared from the indicated strains. The m/z corresponding to the $[M+H]^+$ ion derived from **1** ($C_{48}H_{81}N_9O_8$) and **7** ($C_{52}H_{85}N_{11}O_{12}$) are shown. The intensity scale is 1×10^6 for EICs of **1** and 1×10^5 for EICs of **7**.




Figure S7. MUSCLE alignment of SurE with closely related proteins. MppK (discussed in the text) is a proposed cyclase involved of mannopeptimycin. 4Y7P, 1IKI, 1CEF are PDB accessions for structurally characterised D-peptidases. The active site tetrad Ser-Lys-Tyr-His is indicated by red asterisks.




Figure S8. Maximum likelihood phylogeny of SurE and related proteins. The mid-root phylogeny is based on SurE, type I and Type II thioesterases and β -lactamases. SH-like support values are indicated at nodes as decimal values. The amino acid sequences used here, with the exception of SurE, MppK and the β -lactamase PDB entries (shaded blue), were obtained from ¹⁷. Pink text indicates cis-encoded type II thioesterases. TE_I, type I thioesterase; TE_II, type II thioesterase; P = from PKS system; N = from NRPS system; PN = from PKS-NRPS system; uk = unknown. The scale bar represents 10% sequence divergence.




Figure S9. SDS-PAGE analysis of purified (His)₆SurE from *E. coli* BL21-Gold(DE3). M, marker; F, Ni-NTA column flow through; W1, first wash; W2, second wash; E1-E3, elutions 1-3. Buffers for washing and elution indicated in the methods section.





Figure S10. LC-HRMS analysis of SNAC-surugamide A (**8**). The base peak chromatogram (BPC) and the m/z corresponding to the $[M+H]^+$ ion derived from **8** ($C_{52}H_{90}N_{10}O_9S$) is shown in blue.




Figure S11. The measured (blue) and simulated (orange) $[M+H]^+$ mass spectra for SNAC-surugamide A.




Figure S12. MS2 fragmentation of SNAC-surugamide A (**8**). Mapped fragments are color-coded. Green text indicates an unobserved ion.




Figure S13. ¹H NMR of SNAC-surugamide A.




Figure S14. The measured (red) and simulated (orange) [M+H]⁺ mass spectra for surugamide A produced by SurE in vitro.




Figure S15. MS2 fragmentation of surugamide A produced by SurE in vitro. Green text indicates an unobserved ion.




Figure S16. LC-HRMS analysis of in vitro reactions with **8**. The BPC and EICs for **8** (red, $C_{52}H_{90}N_{10}O_9S$, $[M+H]^{2+}$) and **1** (blue, $C_{48}H_{81}N_9O_8$, $[M+H]^{2+}$) for each sample. Samples include (from top down): **8** alone, **8** + SurE, crude extract from *S. albus* WT, co-injection of **8** + SurE with crude extract from *S. albus* WT.

Table S1. NRPS biosynthetic systems lacking an embedded thioesterase domain and with an adjacent SurE ortholog

Accession	Taxonomy	Number of Modules	BiG-SCAPE gene cluster family
BGCs in the network			
JOCL01000027.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3877	6	1899
LGCU01000069.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3898	6	1899
JNVV01000002.1	<i>Streptomyces flaveolus</i> strain NRRL B-1589	10	1915
KQ948566.1	<i>Streptomyces longwoodensis</i> strain DSM 41677	10	1838
FKJH01000063.1	<i>Streptomyces</i> sp. F-7	10	1838
LN831790.1	<i>Streptomyces leeuwenhoekii</i>	10	1838
JNWX01000027.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL B-16073	6	1899
JOBS01000025.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3558	6	1899
LMWF01000128.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3897	6	1899
JMGX01000001.1	<i>Streptomyces rimosus</i> strain R6-500MV9	6	1899
JOCN01000027.1	<i>Streptomyces lavendulae</i> subsp. <i>lavendulae</i> strain NRRL WC-3532	6	1899
JOJH01000022.1	<i>Streptomyces</i> sp. NRRL WC-3725	10	1915
LWAB01000002.1	<i>Streptomyces</i> sp. H-KF8	10	1838
JODT01000010.1	<i>Streptomyces achromogenes</i> subsp. <i>achromogenes</i> strain NRRL B-2120	10	1915
JOJG01000030.1	<i>Streptomyces</i> sp. NRRL WC-3683	10	1915
JOEX01000030.1	<i>Streptomyces lavendulae</i> subsp. <i>lavendulae</i> strain NRRL B-2775	6	1899
LGCR01000071.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3875	6	1899
CM002273.1.1	<i>Streptomyces</i> sp. PVA 94-07	6	1904
JOGU01000009.1	<i>Streptomyces griseus</i> subsp. <i>griseus</i> strain NRRL F-5621	6	1904
BBNN01000019.1	<i>Streptomyces</i> sp. NBRC 110035	10	1838
CP013219.1	<i>Streptomyces hygrosopicus</i> subsp. <i>limoneus</i>	10	1915
CP016174.1	<i>Amycolatopsis orientalis</i> B-37	9	1851
FOPQ01000016.1	<i>Amycolatopsis regifaucium</i> strain DSM 45072	9	1851
LJJF01000001.1.2*	<i>Streptomyces</i> sp. MJM8645	10	1915
CP006259.1	<i>Streptomyces collinus</i> Tu 365	10	1838
JOIC01000025.1	<i>Streptomyces</i> sp. NRRL F-3307	10	1915
KQ948863.1	<i>Streptomyces bungoensis</i> strain DSM 41781	10	1838
LGUX01000036.1	<i>Streptomyces antibioticus</i> strain NRRL B-2032	10	1915
LMTQ02000010.1	<i>Streptomyces</i> sp. AVP053U2	10	1838
BBOU01000038.16	<i>Streptomyces hygrosopicus</i> subsp. <i>hygrosopicus</i>	10	5
BCAN01000035.1	<i>Streptomyces hygrosopicus</i> subsp. <i>hygrosopicus</i>	10	5
JOBN01000024.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3925	6	1899
LBDA02000012.1	<i>Streptomyces malaysiense</i> strain MUSC 136	10	1915
LGDZ01000181.1	<i>Streptomyces</i> sp. NRRL B-3648	10	1915
FNTM01000001.1	<i>Streptomyces</i> sp. 2133.1	10	1849
BBUZ01000026.1	<i>Streptomyces</i> sp. NBRC 110028	10	5
LAKD02000032.1	<i>Streptomyces antioxidans</i> strain MUSC 164	10	5
JOCM01000023.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3876	6	1899
JOET01000024.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL B-2661	6	1899

JNYK01000022.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL B-8076	6	1899
JOCK01000027.1	<i>Streptomyces peucetius</i> strain NRRL WC-3868	6	1899
KQ948353.1	<i>Streptomyces corchorusii</i> strain DSM 40340	10	1915
LIPD01000005.1	<i>Streptomyces</i> sp. CB02056	9	1915
JOCJ01000019.1	<i>Streptomyces</i> sp. NRRL WC-3744	10	1915
JOCB01000020.1	<i>Streptomyces</i> sp. NRRL S-31	10	1915
JOJJ01000019.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3929	6	1916
CM002271.1.2*	<i>Streptomyces</i> sp. GBA 94-10	18	1821
CP004370.1.2*	<i>Streptomyces albus</i> J1074	18	1821
LGCV01000363.1	<i>Streptomyces rimosus</i> subsp. <i>pseudoverticillatus</i> strain NRRL WC-3896	6	1899
JOBO01000008.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3927	6	1916
CM002271.1.1	<i>Streptomyces</i> sp. GBA 94-10	6	1904
LGCP01000253.1	<i>Streptomyces</i> sp. NRRL WC-3701	6	1899
JOIV01000032.1	<i>Streptomyces</i> sp. NRRL S-1896	10	1915
JOCP01000022.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3880	6	1899
LGUY01000146.1	<i>Kitasatospora aureofaciens</i> strain NRRL B-2658	6	1899
CP004370.1.1	<i>Streptomyces albus</i> J1074	6	1820
CP009802.1.1	<i>Streptomyces</i> sp. FR-008	6	1820
FMZK01000015.1	<i>Streptomyces emeiensis</i> strain CGMCC 4.3504	10	1838
LFVR01000013.1	<i>Streptomyces regensis</i> strain NRRL B-11479	10	1915
JOCO01000023.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3882	6	1899
JOCR01000021.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3900	6	1899
JOIU01000014.1	<i>Streptomyces</i> sp. NRRL S-1022	10	1915
JNWP01000024.1	<i>Streptomyces capuensis</i> strain NRRL B-12337	6	1899
JOBW01000024.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3924	6	1916
CP015588.1	<i>Streptomyces alfalfae</i> ACCC40021	10	1915
JOCH01000022.1	<i>Streptomyces</i> sp. NRRL WC-3703	6	1899
KV757140.1	<i>Streptomyces sporocinereus</i> strain OsiSh-2	10	5
LXIC01000010.1	<i>Streptomyces</i> sp. RTd22	10	5
JOCU01000001.1	<i>Streptomyces flavus</i> strain NRRL WC-3505	10	1915
LN997842.1	<i>Streptomyces reticuli</i>	10	1915
JNYR01000027.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL ISP-5260	6	1899
CP003720.1	<i>Streptomyces hygrosopicus</i> subsp. <i>jinggagensis</i> TL01	10	1915
JOHT01000002.1	<i>Streptomyces</i> sp. NRRL F-5053	6	1906
JODF01000025.1	<i>Streptomyces</i> sp. NRRL S-920	10	1915
FOWC01000006.1	<i>Amycolatopsis rubida</i> strain DSM 44637	9	1918
KB913032.1	<i>Amycolatopsis alba</i> DSM 44262	9	1918
JOBP01000016.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3930	6	1916
JOFU01000020.1	<i>Streptomyces griseofuscus</i> strain NRRL B-5429	10	1915
LGUU01000283.1	<i>Streptomyces decoyicus</i> strain NRRL 2666	10	1849
FNSG01000001.1	<i>Streptomyces</i> sp. 2112.2	10	1849
JOIX01000003.1	<i>Streptomyces</i> sp. NRRL S-337	10	1915
LGDX01000188.1	<i>Streptomyces</i> sp. NRRL WC-3723	10	1915
CP019457.1	<i>Streptomyces lydicus</i> GS93	5	1830

JNZA01000037.1	<i>Streptomyces lydicus</i> strain NRRL ISP-5461	5	1830
JOCC01000027.1	<i>Streptomyces</i> sp. NRRL WC-3702	6	1899
JNWN01000025.1	<i>Streptomyces</i> sp. NRRL B-11253	6	1899
LGCO01000080.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3909	6	1899
FNSO01000004.1	<i>Amycolatopsis tolypomycina</i> strain DSM 44544	10	1919
JPRA01000062.1	<i>Amycolatopsis mediterranei</i> strain HP-130	10	1919
CP009802.1.2*	<i>Streptomyces</i> sp. FR-008	18	1821
KB898235.1	<i>Streptomyces</i> sp. CNY228	18	1821
FNKS01000001.1	<i>Streptomyces</i> sp. KS_16	10	1849
LLZJ01000403.1	<i>Streptomyces violaceusniger</i> strain NRRL F-8817	10	5
FNST01000002.1	<i>Streptomyces melanosporofaciens</i> strain DSM 40318	10	5
B DFA01000034.1	<i>Streptomyces</i> sp. SPMA113	10	5
CP015726.1	<i>Streptomyces</i> sp. RTd22	10	5
CP009438.1	<i>Streptomyces glaucescens</i>	10	1838
JOJM01000018.1	<i>Streptomyces</i> sp. NRRL B-1347	9	1917
FMBX01000012.1	<i>Streptomyces</i> sp. ScaeMP-6W	18	1821
MNPQ01000023.1	<i>Streptomyces albidoflavus</i> strain OsLf-2	18	1821
JOEO01000025.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL B-2626	6	1899
FNTP01000001.1	<i>Streptomyces</i> sp. 2112.3	10	1849
MIBiG_BGC0001792.1	Surugamide A/D (from <i>Streptomyces albus</i>)	18	1821
CP016824.1.1	<i>Streptomyces sampsonii</i> KJ40	18	1821
LGCT01000071.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3899	6	1899
JOFM01000024.1	<i>Streptomyces capuensis</i> strain NRRL B-3501	6	1899
JOCQ01000017.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3904	6	1916
JNWZ01000005.1	<i>Kitasatospora phosalacinea</i> strain NRRL B-16230	4	1893
JODW01000005.1	<i>Streptomyces globisporus</i> subsp. <i>globisporus</i> strain NRRL B-2293	4	1893
FNUJ01000015.1	<i>Amycolatopsis pretoriensis</i> strain DSM 44654	9	1918
MQUQ01000027.1	<i>Amycolatopsis coloradensis</i> strain DSM 44225	9	1918
CP019458.1	<i>Streptomyces autolyticus</i> CGMCC0516	10	5
JJNO01000003.1	<i>Streptomyces rimosus</i> R6-500	6	1899
JNYY01000016.1	<i>Amycolatopsis vancoresmycina</i> strain NRRL B-24208	10	1919
KB913037.1	<i>Amycolatopsis balhimycina</i> FH 1894 strain DSM 44591	10	1919
JOBD01000008.1	<i>Streptomyces lavenduligriseus</i> strain NRRL ISP-5487	10	1915
JOIK01000003.1	<i>Streptomyces hygrosopicus</i> subsp. <i>hygrosopicus</i> strain NRRL B-1477	10	5
LGCS01000311.1	<i>Streptomyces rimosus</i> subsp. <i>rimosus</i> strain NRRL WC-3873	6	1899
CP018627.1	<i>Streptomyces hygrosopicus</i> XM201	10	5
LLZK01000014.1	<i>Streptomyces</i> sp. NRRL S-1521	10	1915
JOGD01000011.1	<i>Streptomyces</i> sp. NRRL S-1868	6	1906
KB891896.1	<i>Streptomyces</i> sp. MspMP-M5	5	1830
BBUZ01000046.1	<i>Streptomyces</i> sp. NBRC 110028	6	1936
CP020567.1	<i>Kitasatospora aureofaciens</i> strain DM-1	6	1936
CP006567.1	<i>Streptomyces rapamycinicus</i> NRRL 5491	10	5
LOBU02000031.1	<i>Amycolatopsis regifaucium</i> strain GY080	9	1851
JTCK01000091.1	<i>Streptomyces</i> sp. CNQ431	6	1904

CM002273.1.2*	Streptomyces sp. PVA 94-07	18	1821
JOER01000020.1	Kitasatospora aureofaciens strain NRRL B-2657	6	1936
JOFK01000006.1	Streptomyces avellaneus strain NRRL B-3447	6	1936
LAYX01000005.1	Streptomyces sp. KE1	5	1904
CP003777.1	Amycolatopsis mediterranei RB	10	1919
CP016824.1.2*	Streptomyces sampsonii KJ40	5	1855
JOII01000014.1	Streptomyces albidoflavus strain NRRL B-1271	5	1855
JOGG01000034.1	Streptomyces sp. NRRL B-5680	6	1936
FNSJ01000001.1	Streptomyces sp. 2314.4	10	1849
FNSB01000002.1	Streptomyces sp. 2224.1	10	1849
KN549147.1	Streptomyces sp. M10	6	1904
JABQ01000025.1	Streptomyces sp. PRh5	10	5
JPLW01000002.1	Amycolatopsis sp. MJM2582	9	1918
CP003410.1	Amycolatopsis orientalis HCCB10007	9	1918
CP019779.1	Streptomyces sp. MOE7	4	1830
JOGN01000041.1	Streptomyces griseus subsp. griseus strain NRRL F-5618	5	1855
MIBiG_BGC0001569.1	Dechlorocuracomycin (from Streptomyces noursei)	6	1810
CP011533.1	Streptomyces noursei ATCC 11455	6	1810
FNTA01000002.1	Amycolatopsis lurida strain DSM 43134	9	1918
JPRF03000087.1	Kitasatospora aureofaciens strain ATCC 10762	6	1936
LBHA01000110.1	Kitasatospora aureofaciens strain NRRL 2209	6	1936
CP017157.1	Streptomyces lydicus 103	5	1830
MVFC01000034.1	Streptomyces tsukubensis strain F601	6	1904
JMQJ01000071.1	Amycolatopsis mediterranei strain DSM 40773	10	1919
JOIQ01000012.1	Streptomyces sp. NRRL F-3213	9	1918
LK022848.1	Streptomyces iranensis	10	5
JODE01000022.1	Streptomyces sp. NRRL S-515	6	1889
JODJ01000024.1	Streptomyces sp. NRRL S-575	6	1889
CP014485.1.2*	Streptomyces albus SM254	18	1821
JMQG01000012.1	Amycolatopsis mediterranei strain DSM 46096	10	1919
LQCI01000007.1	Amycolatopsis regifaucium strain GY080	9	1851
LWSF01000010.1	Amycolatopsis sp. M39	9	1918
JH DU01000021.1	Streptomyces wadayamensis strain A23	5	1855
CP003987.1	Streptomyces sp. 769	6	1810
CP014485.1.1	Streptomyces albus SM254	6	1820
FNSM01000001.1	Streptomyces sp. TLI_105	4	1893
MIBiG_BGC0001814.1	Ulleungmycin (from Streptomyces sp. KCB13F003)	6	1810
FPJG01000006.1	Amycolatopsis australiensis strain DSM 44671	9	1918
Singletons			
ASHX02000001.1	Streptomyces thermolilacinus SPC6	4	0
CP017316.1	Streptomyces rubrolavendulae MJM4426	6	1828
CP019798.1	Streptomyces sp. fd1-xmd	5	1833
CP020563.1	Kitasatospora albolonga YIM 101047	6	1834
FNON01000001.1	Amycolatopsis xylanica strain CPCC 202699	6	1840

JNXP01000027.1	Streptomyces seoulensis strain NRRL B-24310	4	1865
JOHO01000003.1	Streptomyces sp. NRRL S-350	6	1905
KB890716.1	Streptomyces sp. LaPpAH-202	6	1922
KB897508.1	Salinispora pacifica CNY331	5	1924
LGDY01000106.1	Nocardia sp. NRRL S-836	7	1946
LJF01000001.1	Streptomyces sp. MJM8645	6	1952
NBCN01000013.1	Streptomyces sp. CB03238	5	1969

^aAccession numbers provided are for whole genomes or draft genome contigs harboring the BGC

*Denotes accession numbers which have been appended with “.2” in cases where a whole genome harbors more than one SurE-containing BGC.

Table S2. Oligonucleotide primers used in this study

Primer name	Sequence (5' - 3')	Description
DT045	tgaccgggaacaccgtgctcac	Hygromycin resistance cassette
DT046	cggaaggcgttgagatgcagtt	Hygromycin resistance cassette
DT159	aacgtgttcacctgggctc	Identification of Cos994
DT160	acggccgaaaaaaggggcaa	Identification of Cos994
DT161	agggtccgtgggttcagtgggcgaggggacgcagtgattccgggatccgtcgacc	ReDirect primers for deleting surE
DT162	gcgtcgcggggcgcggccggccggccgagtggggcgggtcatgtaggctggagctgcttc	ReDirect primers for deleting surE
DT163a	agctggctcatgcagttcgctc	Verification of Δ surE
DT164a	atcgtgggtcaccatcagctc	Verification of Δ surE
DT167	cggatcgcggggcggccgaaaagaagggcaagttgtattccgggatccgtcgacc	ReDirect primer for deleting surF
DT168	acgccgcgcgagggcgtctccggccccctgccggttcattgtaggctggagctgcttc	ReDirect primer for deleting surF
DT171	acttctcaaccacaccacg	Verification of Δ surF
DT172	cggttcaacgtgtttcaact	Verification of Δ surF
DT186	tggacagttgcctgctcgt	Sequencing surE in pDT2
DT206	atctcatatggtgggtgccgagggggcggga	Construction of pET28-surE
DT210	atcacatagtggtgggtgccgagggggcggga	Construction of pDT2
DT211	atctaaacttcagagccggtgcattggccc	Construction of pDT2
DT213	atcactcagatcagagccggtgcattggccc	Construction of pET28-surE
RFS115	cattcttcgatcccgcct	Apramycin resistance cassette
RFS116	ctcttccgtagcgtcc	Apramycin resistance cassette
RFS184	ccattattatcatgacattaa	Cos994 insert-end sequencing
RFS185	gtccgtggaatgaacaatgg	Cos994 insert-end sequencing
RFS582	agcccagcccgagcacg	Sequencing surE in pDT2

*Non-homologous sequences are bolded and restriction endonuclease sites are underlined

Table S3. Bacterial strains, cosmids and plasmids used in this study

Strain/cosmid/plasmid	Description	Reference
Streptomyces		
S. albus S4	Streptomyces albus S4 wildtype	18
ΔsurE	S4 surE mutant, Apr ^R	This study
ΔsurE attB ΦBT1::pDT2	S4 surE mutant complemented with surE expressed from the ermE* promoter; Apr ^R , Hyg ^R	This study
ΔsurF	S4 surF mutant, Apr ^R	This study
Escherichia coli		
BL21-Gold(DE3)	Protein production host	Agilent Technologies
GB0R-red	RecET recombineering host	6
ET12567	Non-methylating host to for conjugal transfer of DNA into Streptomyces (dam, dcm, hsdM); Cam ^R	19
XL10-Gold	General cloning host	Agilent Technologies
Cosmids		
Supercos1	Cosmid backbone for S. albus S4 Cos994; Carb ^R , Kan ^R	Stratagene
Cos994	Supercos1 derivative spanning the surugamide gene cluster from surF into surB; Carb ^R , Kan ^R	This study
Cos994-ΔsurE	Cos994 derivative with surE deletion; Carb ^R , Kan ^R , Apr ^R	This study
Cos994-ΔsurF	Cos994 derivative with surF deletion; Carb ^R , Kan ^R , Apr ^R	This study
Plasmids		
pDT2	pIJ10257 derivative containing the surE coding sequence cloned into the NdeI-HindIII sites; Hyg ^R	This study
pET28a	Commercial protein production vector, Kan ^R	Agilent Technologies
pET28-surE	pET28a derivative containing the surE gene cloned into the NdeI-XhoI restriction sites; Kan ^R	
pIJ773	ReDirect PCR template for the aac(3)IV + oriT cassette	2
pIJ10257	pMS81 derivative containing ermE*p, integrates into the ΦBT1 attB site in Streptomyces; Hyg ^R	7
pUZ8002	Encodes the conjugation machinery for mobilisation of plasmids from E. coli to Streptomyces; Kan ^R	19

Apr, apramycin; Hyg, Hygromycin; Cam, chloramphenicol; Kan, kanamycin; Carb, carbenicillin; oriT, origin of conjugal transfer

References

- (1) Kieser, T. B., Buttner, M. J., Chater, K. F., Hopwood, D. A. 2000. Practical Streptomyces genetics. The John Innes Foundation, Norwich, United Kingdom.
- (2) Gust, B., Challis, G. L., Fowler, K., Kieser, T., and Chater, K. F. (2003) PCR-targeted Streptomyces gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin. *Proceedings of the National Academy of Sciences* 100, 1541–1546.
- (3) Seipke, R. F., Patrick, E., and Hutchings, M. I. (2014) Regulation of antimycin biosynthesis by the orphan ECF RNA polymerase σ factor (AntA.). *PeerJ* 2, e253.
- (4) Seipke, R. F., Barke, J., Brearley, C., Hill, L., Yu, D. W., Goss, R. J. M., and Hutchings, M. I. (2011) A Single Streptomyces Symbiont Makes Multiple Antifungals to Support the Fungus Farming Ant *Acromyrmex octospinosus*. *PLoS ONE* (Yu, J.-H., Ed.) 6, e22028–8.
- (5) Seipke, R. F., Crossman, L., Drou, N., Heavens, D., Bibb, M. J., Caccamo, M., and Hutchings, M. I. (2011) Draft genome sequence of Streptomyces strain S4, a symbiont of the leaf-cutting ant *Acromyrmex octospinosus*. *J. Bacteriol.* 193, 4270–4271.
- (6) Fu, J., Bian, X., Hu, S., Wang, H., Huang, F., Seibert, P. M., Plaza, A., Xia, L., Müller, R., Stewart, A. F., and Zhang, Y. (2012) Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting. *Nat Biotechnol* 30, 440–446.
- (7) Hong, H.-J., Hutchings, M. I., Hill, L. M., and Buttner, M. J. (2005) The role of the novel Fem protein VanK in vancomycin resistance in *Streptomyces coelicolor*. *J Biol Chem* 280, 13055–13061.
- (8) Liu, J., Zhu, X., Seipke, R. F., and Zhang, W. (2015) Biosynthesis of antimycins with a reconstituted 3-formamidosalicylate pharmacophore in *Escherichia coli*. *ACS Synth. Biol.* 4, 559–565.

- (9) Medema, M. H., Medema, M. H., Takano, E., Takano, E., Breitling, R., and Breitling, R. (2013) Detecting Sequence Homology at the Gene Cluster Level with MultiGeneBlast. *Molecular Biology and Evolution* 30, 1218–1223.
- (10) Seemann, T. (2014) Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068–2069.
- (11) Joynt, R., and Seipke, R. F. (2018) A phylogenetic and evolutionary analysis of antimycin biosynthesis. *Microbiology* 164, 28–39.
- (12) Blin, K., Wolf, T., Chevrette, M. G., Lu, X., Schwalen, C. J., Kautsar, S. A., Suarez Duran, H. G., de los Santos, E. L. C., Kim, H. U., Nave, M., Dickschat, J. S., Mitchell, D. A., Shelest, E., Breitling, R., Takano, E., Lee, S. Y., Weber, T., and Medema, M. H. (2017) antiSMASH 4.0—improvements in chemistry prediction and gene cluster boundary identification. *Nucleic Acids Research* 45, W36–W41.
- (13) Navarro-Muñoz, J., Selem Mojica, N., Mullaney, M., Kautsar, S., Tryon, J., Parkinson, E., De Los Santos, E., Yeong, M., Cruz-Morales, P., Abubucker, S., Roeters, A., Lokhorst, W., Fernandez-Guerra, A., Teresa Dias Cappelini, L., Thomson, R., Metcalf, W., Kelleher, N., Barona-Gómez, F., and Medema, M. H. (2018) A computational framework for systematic exploration of biosynthetic diversity from large-scale genomic data. *bioRxiv* 1–22.
- (14) Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Research* 13, 2498–2504.
- (15) Edgar, R. C. (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Research* 32, 1792–1797.
- (16) Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., and Gascuel, O. (2010) New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst. Biol.* 59, 307–321.

- (17) Nakamura, H., Wang, J. X., and Balskus, E. P. (2015) Assembly line termination in cylindrocyclophane biosynthesis: discovery of an editing type II thioesterase domain in a type I polyketide synthase. *Chem Sci* 6, 3816–3822.
- (18) Barke, J., Seipke, R. F., Grüşchow, S., Heavens, D., Drou, N., Bibb, M. J., Goss, R. J. M., Yu, D. W., and Hutchings, M. I. (2010) A mixed community of actinomycetes produce multiple antibiotics for the fungus farming ant *Acromyrmex octospinosus*. *BMC Biol.* 8, 109.
- (19) MacNeil, D. J., Gewain, K. M., Ruby, C. L., Dezeny, G., Gibbons, P. H., and MacNeil, T. (1992) Analysis of *Streptomyces avermitilis* genes required for avermectin biosynthesis utilizing a novel integration vector. *Gene* 111, 61–68.